Brokers Offer Predictions for CLDX Q1 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Celldex Therapeutics in a research note issued on Thursday, February 26th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings per share of ($1.27) for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q2 2026 earnings at ($1.30) EPS and FY2027 earnings at ($5.53) EPS.

CLDX has been the subject of a number of other reports. Stifel Nicolaus restated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Finally, Barclays upped their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.20.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $30.64 on Friday. The company has a market cap of $2.04 billion, a P/E ratio of -7.88 and a beta of 1.24. Celldex Therapeutics has a 12 month low of $14.40 and a 12 month high of $31.31. The company has a 50-day moving average of $25.61 and a 200-day moving average of $25.43.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 39.67%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Simplify Asset Management Inc. acquired a new position in Celldex Therapeutics during the 3rd quarter valued at about $2,199,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Celldex Therapeutics during the second quarter valued at approximately $1,188,000. Corient Private Wealth LLC acquired a new position in shares of Celldex Therapeutics during the second quarter worth approximately $4,105,000. American Century Companies Inc. boosted its position in shares of Celldex Therapeutics by 24.7% during the second quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock worth $15,873,000 after buying an additional 154,664 shares during the period. Finally, TFG Asset Management GP Ltd grew its holdings in Celldex Therapeutics by 21.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 316,150 shares of the biopharmaceutical company’s stock worth $6,434,000 after buying an additional 55,150 shares in the last quarter.

Key Headlines Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Completed enrollment in global Phase 3 EMBARQ program (EMBARQ‑CSU1 & EMBARQ‑CSU2) for barzolvolimab — 1,939 patients across 43 countries, the largest antihistamine‑refractory CSU program, which de‑riscales the timeline for potential 2026 data readouts. Completion of Phase 3 Enrollment
• Positive Sentiment: Analysts showing conviction: Stifel Nicolaus reaffirmed a Buy and raised its price target to $68 (previously $58) — implying ~122% upside from the current price level — which can support investor interest and buying pressure. Stifel Rating/Price Target
• Positive Sentiment: Morgan Stanley (via TipRanks summary) and other analysts have reiterated Buy ratings, citing early EMBARQ enrollment and multiple 2026 data catalysts that improve the risk/reward profile. Analyst Commentary
• Neutral Sentiment: Consensus on analyst coverage is mixed‑to‑positive — sites report an average rating around “Moderate Buy,” which supports a constructive medium‑term view but is not a unanimous bullish signal. Analyst Consensus
• Neutral Sentiment: Short interest reporting appears anomalous / immaterial in recent data (reported as zero), so it likely did not meaningfully influence today’s move. Short Interest Note
• Negative Sentiment: Q4 2025 results missed expectations: CLDX reported ($1.22) EPS vs. ($1.00) consensus and revenue of $0.12M vs. $1.53M expected — the miss increases near‑term financial uncertainty and likely drove intraday selling pressure despite the clinical progress. Earnings Press Release

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.